Investment Advisors Argue Private Equity Offer For Biomet Is Too Low
This article was originally published in The Gray Sheet
Executive Summary
An investor advisor group is urging Biomet shareholders to reject a proposed $10.9 billion private equity buyout because it represents too small a premium over the orthopedic company's value